: A Novel Molecular Biomarker Predicts Tumor Microenvironment, Molecular Subtype, and Prognosis in Bladder Cancer.

BACKGROUND

Thioesterase superfamily member 6 () has been implicated in the development and progression of various cancers. However, prior research emphasized on its regulatory role merely, we aim to investigate the effect of gene on the immunological role and its relationship with molecular subtype in bladder cancer (BLCA).

METHODS

Through pan-cancer analysis, we explored the expression pattern and immunological role using The Cancer Genome Atlas (TCGA) database. In addition, we performed a correlation of and its immunological functions, including immunomodulators, immune checkpoints, cancer immunity cycles, T cell inflamed score, and tumor-infiltrating immune cells in the BLCA tumor microenvironment (TME) based on TCGA and BLCA microarray cohort from Xiangya Hospital. We also assessed the accuracy of in predicting the molecular subtype and its response to different interventions in BLCA. Finally, we computed and validated a prediction model established by -related different expressed immune-related genes that might help in BLCA prognosis.

RESULTS

led to immunosuppression in BLCA TME. Furthermore, there was a downregulation in the immunological functions. Besides, could effectively distinguish BLCA molecular subtypes, and low expression implied basal subtype that was more effective to several interventions, such as immune checkpoint blockade (ICB) therapies, neoadjuvant chemotherapy, and radiotherapy. While high expression indicated luminal subtype, hyperprogression and better response to targeted therapies, such as blocking and several immune-inhibited oncogenic pathways.

CONCLUSIONS

may be with potential immune-modulating properties and may become a potential new immunotherapy target for BLCA. could accurately predict the molecular subtype of BLCA, which was helpful for guiding the treatment. Simultaneously, the prediction model may exhibit an excellent predictive value in patients with BLCA.